Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 45Lymphoma, Mantle-Cell 22Waldenstrom Macroglobulinemia 12Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Follicular 10Lymphoma, B-Cell 10Leukemia 10Recurrence 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma 6Neoplasms 4Hodgkin Disease 4Leukemia, Prolymphocytic 3Leukemia, Lymphoid 3Leukemia, B-Cell 3Chromosome 17 deletion 3Burkitt Lymphoma 3Bronchiolitis Obliterans Syndrome 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Hematologic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1

Interventions

Cyclophosphamide 59Dexamethasone 56Melphalan 48Peripheral Blood Stem Cell Transplantation 37Busulfan 34Bortezomib 32fludarabine phosphate 29Lenalidomide 27Filgrastim 27Tacrolimus 24Antilymphocyte Serum 24Thalidomide 22Mycophenolic Acid 22Radiotherapy 21Methotrexate 15Cyclosporine 15Etoposide 14sargramostim 13Granulocyte Colony-Stimulating Factor 11Whole-Body Irradiation 10Methylprednisolone 10Interferon-alpha 10fludarabine 9daratumumab 9Carmustine 9carfilzomib 7Rituximab 7Prednisone 7Cytarabine 7Cord Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Plasma Cell × ibrutinib × Clear all
NCT02943473 2020-12-16

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

Icahn School of Medicine at Mount Sinai

Phase 2 Terminated
9 enrolled 6 charts
Plasma cell

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡